GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Novelion Therapeutics Inc (STU:QLTA) » Definitions » ROCE %

Novelion Therapeutics (STU:QLTA) ROCE % : 0.00% (As of Mar. 2019)


View and export this data going back to . Start your Free Trial

What is Novelion Therapeutics ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Novelion Therapeutics's annualized ROCE % for the quarter that ended in Mar. 2019 was 0.00%.

Novelion Therapeutics ROCE % Historical Data

The historical data trend for Novelion Therapeutics's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novelion Therapeutics ROCE % Chart

Novelion Therapeutics Annual Data
Trend Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -20.95 -18.56 -14.71 -23.70 -42.67

Novelion Therapeutics Quarterly Data
Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -27.78 -25.55 -33.42 - -

Novelion Therapeutics ROCE % Calculation

Novelion Therapeutics's annualized ROCE % for the fiscal year that ended in Dec. 2018 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2018 )  (A: Dec. 2017 )(A: Dec. 2018 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2018 )  (A: Dec. 2017 )(A: Dec. 2018 )
=-42.118/( ( (312.077 - 54.278) + (300.367 - 360.731) )/ 2 )
=-42.118/( (257.799+-60.364)/ 2 )
=-42.118/98.7175
=-42.67 %

Novelion Therapeutics's ROCE % of for the quarter that ended in Mar. 2019 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2019 )  (Q: Dec. 2018 )(Q: Mar. 2019 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2019 )  (Q: Dec. 2018 )(Q: Mar. 2019 )
=-56.596/( ( (300.367 - 360.731) + (302.776 - 392.461) )/ 2 )
=-56.596/( ( -60.364 + -89.685 )/ 2 )
=-56.596/-75.0245
=0 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2019) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Novelion Therapeutics  (STU:QLTA) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Novelion Therapeutics ROCE % Related Terms

Thank you for viewing the detailed overview of Novelion Therapeutics's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Novelion Therapeutics (STU:QLTA) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Novelion Therapeutics Inc (STU:QLTA) » Definitions » ROCE %
Comparable Companies
DFFN TSXV:KLY TSXV:QPT ASX:PTX ROCO:4197 XSAT:WNT PTIX IST:RTALB TROV NOVN MATN LSE:TRX ASX:NYR ATOS TSXV:BCT JAGX TSX:CTX ROCO:6744 ACHV EMBI
Traded in Other Exchanges
N/A
Address
c/o Norton Rose Fulbright, 1800 West Georgia Street, Suite 510, Vancouver, BC, CAN, V6B 0M3
Website
http://www.novelion.com
Headquartered in Vancouver, Canada, QLT is a biotechnology company that researches and develops products used to treat conditions of the eye. After a recent board change, QLT divested its only marketed product, a laser treatment called Visudyne for the treatment of wet age-related macular degeneration and subfoveal choroidal neovascularization. QLT also earns royalty payments on other certain previously divested products. Following recent pipeline changes, the company currently has one product in development for two rare eye conditions.